These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 2493162)

  • 1. The economics of mild hypertension programmes.
    Edgar MA; Schnieden H
    Soc Sci Med; 1989; 28(3):211-22. PubMed ID: 2493162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention?
    Malcolm LA; Kawachi I; Jackson R; Bonita R
    N Z Med J; 1988 Apr; 101(843):167-71. PubMed ID: 3128747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study.
    Wonderling D; McDermott C; Buxton M; Kinmonth AL; Pyke S; Thompson S; Wood D
    BMJ; 1996 May; 312(7041):1269-73. PubMed ID: 8634617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study.
    Langham S; Thorogood M; Normand C; Muir J; Jones L; Fowler G
    BMJ; 1996 May; 312(7041):1265-8. PubMed ID: 8634616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis.
    McManus RJ; Mant J; Roalfe A; Oakes RA; Bryan S; Pattison HM; Hobbs FD
    BMJ; 2005 Sep; 331(7515):493. PubMed ID: 16115830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome.
    Shackley P; McGuire A; Boyd PA; Dennis J; Fitchett M; Kay J; Roche M; Wood P
    J Public Health Med; 1993 Jun; 15(2):175-84. PubMed ID: 7688977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for mild hypertension: costs and benefits.
    Bryers F; Hawthorne VM
    J Epidemiol Community Health (1978); 1978 Sep; 32(3):171-4. PubMed ID: 101569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study.
    Boer R; de Koning H; Threlfall A; Warmerdam P; Street A; Friedman E; Woodman C
    BMJ; 1998 Aug; 317(7155):376-9. PubMed ID: 9694752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
    van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
    Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for hypertension.
    Littenberg B; Garber AM; Sox HC
    Ann Intern Med; 1990 Feb; 112(3):192-202. PubMed ID: 2136982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening infants for hearing loss--an economic evaluation.
    Brown J
    J Epidemiol Community Health; 1992 Aug; 46(4):350-6. PubMed ID: 1431705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling future capacity needs and spending on colonoscopy in the English bowel cancer screening programme.
    Nnoaham KE; Lines C
    Gut; 2008 Sep; 57(9):1238-45. PubMed ID: 18441004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial.
    Søgaard R; Lindholt JS
    Br J Surg; 2018 Sep; 105(10):1283-1293. PubMed ID: 29691840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare and patient costs of a proactive chlamydia screening programme: the Chlamydia Screening Studies project.
    Robinson S; Roberts T; Barton P; Bryan S; Macleod J; McCarthy A; Egger M; Sanford E; Low N;
    Sex Transm Infect; 2007 Jul; 83(4):276-81. PubMed ID: 17229792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costing model for neonatal screening and diagnosis of haemoglobinopathies.
    Cronin EK; Normand C; Henthorn JS; Hickman M; Davies SC
    Arch Dis Child Fetal Neonatal Ed; 1998 Nov; 79(3):F161-7. PubMed ID: 10194984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic considerations in the management of mild hypertension.
    Weinstein MC; Stason WB
    Ann N Y Acad Sci; 1978 Mar; 304():424-40. PubMed ID: 101118
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.